Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial

OBJECTIVES: To develop a new Chinese medicine (CM)-based drug and to evaluate its safety and effect for suppressing acute respiratory distress syndrome (ARDS) in COVID-19 patients. METHODS: A putative ARDS-suppressing drug Keguan-1 was first developed and then evaluated by a randomized, controlled t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jia-bo, Wang, Zhong-xia, Jing, Jing, Zhao, Peng, Dong, Jing-hui, Zhou, Yong-feng, Yang, Guang, Niu, Ming, Zhao, Xu, Jiang, Tian-jun, Bi, Jing-feng, Xu, Zhe, Zhang, Ping, Wu, Dan, Bai, Zhao-fang, Guo, Yu-ming, Yu, Si-miao, Sun, Yong-qiang, Zhang, Zi-teng, Zhan, Xiao-yan, Li, Peng-yan, Ding, Jin-biao, Zhao, Peng-fei, Song, Xue-ai, Tang, Jian-yuan, He, Dong-chu, Chen, Zhu, Qin, En-qiang, Wang, Rui-lin, Xiao, Xiao-he
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364292/
https://www.ncbi.nlm.nih.gov/pubmed/32676976
http://dx.doi.org/10.1007/s11655-020-3426-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364292/
https://www.ncbi.nlm.nih.gov/pubmed/32676976
http://dx.doi.org/10.1007/s11655-020-3426-7

Ejemplares similares